Home » News » FTSE 100 » Hikma Pharmaceuticals appoints Douglas Hurt as Non-Executive Director

Hikma Pharmaceuticals appoints Douglas Hurt as Non-Executive Director

Hikma Pharmaceuticals PLC (LON:HIK) today announced the appointment of Douglas Hurt as an independent non-executive director effective 1 May 2020.  Over the course of 2020, Douglas will assume responsibility for chairing the Audit Committee.

During his executive career, Douglas served as Finance Director of IMI plc, the global engineering group, from 2006 to 2015. Prior to this, he held a number of senior finance and general management positions at GlaxoSmithKline plc, which he joined in 1983, previously having worked at Price Waterhouse. His career has included several years working in the US as the Chief Financial Officer and significant experience in European businesses as an Operational and Regional Managing Director.

Douglas is the Senior Independent Director and Chairman of the Audit Committee at Vesuvius PLC and Countryside Properties PLC.  He is a non-executive director and Chairman of the Audit Committee of the British Standards Institution.   Douglas served as Senior Independent Director and Chairman of the Audit Committee of Tate & Lyle plc until July 2019.

Douglas is a Chartered Accountant and holds an MA(Hons) in Economics from Cambridge University.

‘I am very pleased that Douglas will be joining Hikma’s Board.  He brings a wealth of experience, particularly in relation to operational and financial management, reporting, risk and leadership of audit committees.’ said Said Darwazah, Executive Chairman. ‘Over the course of 2020, we will undertake the transition of the Audit Committee chair to Douglas and the role of Senior Independent Director to Pat Butler.’

Join us on our new LinkedIn page

Follow us on LinkedIn